Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
ConditionStage III Colon Cancer
Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorNRG Oncology
About this trial
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Eligibility criteria
Qualifiers
Absolute neutrophil count (ANC) must be greater than or equal to 1500/mm3;
Participants with benign ethnic neutropenia (BEN): ANC less than 1300 mm3 are eligible.
BEN (also known as constitutional neutropenia) is an inherited cause of mild or moderate neutropenia that is not associated with any increased risk for infections or other clinical manifestations. BEN is referred to as ethnic neutropenia because of its increased prevalence in people of African descent and other specific ethnic groups.
Platelet count must be greater than or equal to 100,000/mm3; and
Disqualifiers
None
Trial design
Treatments tested in this trial
- Signatera test
- mFOLFOX6 3-6 month
- CAPOX 3 month
- mFOLFIRINOX
- mFOLFOX6 6 month
- CAPOX 6 month
Treatment groups
1,912 Participants
are divided into 4 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov